Tharimmune - THAR Operating profit EBITDA
This EBITDA chart, featuring data from GURU.Markets, reveals the strategy of Tharimmune, Inc. (THAR) to develop antibodies for the treatment of hepatic pruritus within a protected niche. The current metric level stands at 0.00, confirming a lack of commercial sales and a reliance on investment. Meanwhile, the biotech's success is based on clinical data, remaining independent of economic cycles.
Tharimmune (THAR) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Capital Tharimmune, Inc.|THAR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Tharimmune Inc|THAR - Company Aggregate Debts|Debts to Book Capitalization Tharimmune|THAR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Tharimmune|Interim Coverage Ratio tharimmune.com
- earnings and market ratios statistics:
THAR - Company Net Income|Future Profit Tharimmune, Inc.|THAR - Price to Earnings Ratio|Projected Price to Earnings tharimmune.com|THAR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Tharimmune|THAR - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Tharimmune|THAR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months tharimmune.com|THAR - Net earnings per share growth this year|Expected earnings per share trend next year Tharimmune, Inc.
Summary company analytics:THAR (Tharimmune Corporation)
For Tharimmune, Inc. (THAR), the ability to generate cash is critical amid logistical risks and a dependence on Asian component supplies. By analyzing the recorded EBITDA level, an investor assesses the business's net operating efficiency excluding debt load and depreciation, which allows for the identification of hidden liquidity contraction prior to the publication of financial statements and determines the company's margin of safety against market shocks.
Competitors of Tharimmune, Inc. (THAR)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit before deduction of amortization PSNL (Personalis, Inc.)|Company profit before taxes, interest and amortization ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Income before deduction of interest, taxes and amortization YMAB|Aura Bio - Operating profit EBITDA|CADL - Operating profit EBITDA|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|SELLAS Life Sciences Group - Income before deduction of interest, taxes and amortization|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Citius Oncology Inc. (CTOR) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Operating profit before deduction of amortization Protara Tx TARA|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|WHWK - Operating profit before deduction of amortization|TCRX: Operating profit before deduction of amortization|CSBR - Operating profit EBITDA|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CVM|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Profit before interest, taxes and amortization radiopharmtheranostics.com RADX|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|ANL (adlainortye.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA VERU (Veru Pharma)|Operating income before deduction of amortization Tempest Therapeutics Corp (TPST)|XLO - Profit before payment of interest, taxes and amortization|RENB (Renovaro Inc.) - Operating profit before amortization|MURA: Operating profit EBITDA|Operating profit before deduction of amortization Kairos Pharma|Operating profit before deduction of amortization OKUR|CytoMed (GDTC) - Operating income before deduction of amortization|Operating profit before deduction of amortization CRIS (Curis, Inc.)|Company profit before taxes, interest and amortization APLM|Operating profit EBITDA ADVB (Advanced Biomed)|Income before deduction of interest, taxes and amortization GNPX|Calidi Bio - Operating profit EBITDA|SBFM - Operating profit EBITDA|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|salariuspharma.com - Income before deduction of interest, taxes and amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization AON (AONC)|Operating profit EBITDA BGNE|Operating profit EBITDA Checkpoint Therapeutics Inc (CKPT)|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD: Operating profit before amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|Profit before interest, taxes and amortization MorphoSys Corporation (MOR)|Profit before payment of interest, taxes and amortization NAYA Biosciences|AAPGV: Income before deduction of interest, taxes and amortization
